Formats
  1. Journal Article (66975)
  2. Meeting Abstract (33621)
  3. Book Section (5116)
  4. Review (3781)
  5. Editorial (2185)
  6. Conference Paper (1531)
  7. Correspondence (669)
  8. Guidelines (666)
  9. Research Letter (554)
  10. Book Whole (345)
  11. Miscellaneous (340)
Groups
  1. Department of Medicine (39123)
  2. GSK Faculty (22500)
  3. Solid Tumor Oncology Division (22113)
  4. Surgery (21304)
  5. Survivorship Research (15795)
  6. Sloan Kettering Institute Faculty (15665)

More Groups

People
  1. Marc Ladanyi (1328)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1053)

More People

Years
  1. 2026 (1)
  2. 2025 (2315)
  3. 2024 (5382)
  4. 2023 (5808)
  5. 2022 (6169)
  6. 2021 (5720)

More Years

Publications
  1. Journal of Clinical Oncology (8596)
  2. Blood (4954)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2614)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1814)

More Publications

Publishers
  1. Elsevier Inc. (13867)
  2. American Society of Clinical Oncology (9180)
  3. Springer (7199)
  4. Nature Publishing Group (6392)
  5. American Association for Cancer Research (6014)
  6. Elsevier Science, Inc. (5526)

More Publishers

Results (115783)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial
    Meeting Abstract

    Powell, M. A.; Filiaci, V. L.; Hensley, M. L.; Huang, H. Q.; Moore, K. N.; Tewari, K. S.; Copeland, L. J.; Secord, A. A.; Mutch, D. G.; Santin, A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase II study of tepotinib in NSCLC patients with METex14 mutations
    Meeting Abstract

    Paik, P. K.; Veillon, R.; Cortot, A. B.; Felip, E.; Sakai, H.; Mazieres, J.; Griesinger, F.; Horn, L.; Senellart, H.; Van Meerbeeck, J. P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Pal, S. K.; McDermott, D. F.; Atkins, M. B.; Escudier, B.; Rini, B. I.; Motzer, R. J.; Fong, L.; Joseph, R. W.; Oudard, S.; Ravaud, A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors
    Meeting Abstract

    Papadopoulos, K. P.; Autio, K. A.; Golan, T.; Dobrenkov, K.; Chartash, E.; Li, X. N.; Wnek, R.; Long, G. V.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Park, W.; Wong, W.; Yu, K. H.; Varghese, A. M.; Riaz, N.; Balachandran, V. P.; El Dika, I. H.; Raj, N. P.; Khalil, D.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Efficacy of ramucirumab and docetaxel given either before or after immune checkpoint inhibitors in patients with lung cancers
    Meeting Abstract

    Offin, M.; Xu, C.; Jain, H.; Makhnin, A.; Hayes, S. A.; Plodkowski, A. J.; Halpenny, D.; Rudin, C. M.; Kris, M. G.; Drilon, A. E.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy
    Meeting Abstract

    Owen, C. N.; Larkin, J. M. G.; Shoushtari, A. N.; Carlino, M. S.; Blank, C. U.; Lee, B.; Mangana, J.; Atkinson, V.; Millward, M.; Zaman, F.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Exercise trends among previously non-exercising breast cancer survivors: Analysis of an ethnically diverse sample
    Meeting Abstract

    Oza, S.; Blinder, V. S.; Tran, C.; Patil, S.; Gany, F.; Roberts, N.; Kampel, L. J.; Malik, M.; Bao, T.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC)
    Meeting Abstract

    Page, D. B.; Kim, I. K.; Chun, B.; Redmond, W. L.; Martel, M.; Mori, M.; Wadell, D.; Moxon, N.; Mellinger, S. L.; Urba, W. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228
    Meeting Abstract

    Paik, P. K.; Ahn, L. S. H.; Ginsberg, M. S.; Plodkowski, A. J.; Kim, R.; Doyle, L. A.; Rudin, C. M.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save